Edwards Lifesciences (EW) EBIT Margin (2009 - 2026)

Edwards Lifesciences' EBIT Margin history runs 18 years deep, the most recent figure standing at 28.97% for Q1 2026.

• In Q1 2026, EBIT Margin rose 102.0% year-over-year to 28.97%; the TTM figure through Mar 2026 stood at 21.37% (down 443.0% YoY), while the FY2025 annual figure was 20.84%, down 451.0% from the prior year.
• EBIT Margin was 28.97% for Q1 2026 at Edwards Lifesciences, up from 9.63% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 45.99% in Q4 2022 to a low of 9.63% in Q4 2025.
• Historically, EBIT Margin has averaged 27.44% across 5 years, with a median of 27.38% in 2023.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin surged 1783 bps in 2022, then plunged 1860 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 45.99% in 2022, then slumped by 40 bps to 27.38% in 2023, then fell by 18 bps to 22.56% in 2024, then tumbled by 57 bps to 9.63% in 2025, then surged by 201 bps to 28.97% in 2026.
• The last three EBIT Margin figures came in at 28.97% (Q1 2026), 9.63% (Q4 2025), and 19.77% (Q3 2025), per Business Quant data.